Dexamethasone Reduces Glycolysis and Inflammation in Human Macrophages Infected With Mycobacterium avium Without...

Area of Science:

• Immunology
• Metabolic pathways
• Microbial pathogenesis

Background:

• Nontuberculous mycobacterial infections cause persistent inflammation and require lengthy treatment.
• Current therapeutic strategies lack host-directed approaches to manage inflammation.
• Host immune responses, particularly macrophage metabolism, play a critical role in disease progression.

Purpose of the Study:

• To investigate the metabolic effects of dexamethasone on Mycobacterium avium-infected human macrophages.
• To determine if dexamethasone can modulate host inflammatory responses without impairing bacterial control.
• To explore dexamethasone as a potential host-directed therapeutic strategy.

Main Methods:

• Metabolic flux analysis was employed to study macrophage metabolism.
• Human monocyte-derived macrophages were infected with Mycobacterium avium.
• Dexamethasone treatment effects on metabolic enzymes, cytokine production, and bacterial load were assessed.

Main Results:

• Dexamethasone suppressed Mycobacterium avium-induced glycolysis in human macrophages.
• The drug reduced the expression of key metabolic enzymes involved in glycolysis.
• Proinflammatory cytokine production was decreased by dexamethasone, but bacterial control was unaffected.

Conclusions:

• Suppression of macrophage glycolytic metabolism by dexamethasone can be achieved without compromising the control of Mycobacterium avium infection.
• Dexamethasone demonstrates potential as a host-directed therapy to mitigate inflammation in nontuberculous mycobacterial diseases.
• Further research is warranted to explore dexamethasone's role in balancing host defense and inflammation.